The main objective of this Core is to provide expert pathology services, in coordination with prospective processing, database tracking, storage, and optimal distribution of serial biospecimens from AML and MDS patients to support Core C and all 4 of the GAML Projects. After enrollment of AML and MDS patients by Core A (Clinical Database), bone marrow, peripheral blood leukocytes, serum/plasma, skin, and oral mucosa biospecimens are processed and banked by Core B (Specimen Database). These specimens and their derivatives will serve as the basis for genome and transcriptome analyses and immunological assays in Core C (Sequencing and Analysis) and Projects 1-4. This Biobanking Core will maintain and expand its comprehensive database that annotates each specimen with information related to histopathology, disease status, date collected/processed/distributed, processing performed, parent/derived specimen linkage, quantity, quality, and availability. All specimens are anonymously linked to the patient of origin through unique patient identifier numbers. Pathology expertise provided by Core B ensures the diagnostic accuracy of patient specimens, optimal selection of malignant and normal tissues, and maintenance of quality control (QC) and quality assurance (QA) standards and procedures within a CAP-accredited laboratory environment.
Specific Aim /Core Service 1: We will prospectively process, annotate, and store serial biospecimens and derivatives from all AML and MDS patients enrolled on the GAML protocol. Procedures that are customized and validated for GAML Projects will be used. Viably cryopreserved cells will be banked for single cell RNA-seq, culture expansion, flow cytometry, and immunologic assays. We will isolate high quality DNA/RNA for genome, epigenome and transcriptome studies.
Specific Aim /Core Service 2: We will provide expert pathology review and database tracking to identify and distribute biospecimens for GAML studies. Core B will use its biospecimen database to provide histopathology, disease status, quality, quantity, and availability data in real-time to enable optimal utilization the GAML Projects and Core C. Histopathology services and pathology review will ensure accurate diagnostic information, provide macro/microdissection of archived tissues, and optimal specimen selection and assembly of pathological subsets for GAML Projects.
Core B Specimen Database The goals of the Specimen Database Core (Core B) are fundamental to all Projects (1-4) of the Genomics of AML proposal. In addition to providing expert pathology services, Core B will prospectively process, store, track, and distribute serial AML and MDS biospecimens from GAML patients at key clinical points (diagnosis, progression, relapse), using GAML-customized procedures that conform to College of American Pathology (CAP) accreditation standards and NCI?s Best Practices. Through these services, Core B will achieve objectives that are crucial for the goals of this program project: a greater understanding of the molecular pathogenesis of MDS and AML as a means to improve risk assessment and identify novel therapeutic targets for these aggressive diseases.
|Duncavage, Eric J; Jacoby, Meagan A; Chang, Gue Su et al. (2018) Mutation Clearance after Transplantation for Myelodysplastic Syndrome. N Engl J Med 379:1028-1041|
|Schroeder, Mark A; Choi, Jaebok; Staser, Karl et al. (2018) The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. Biol Blood Marrow Transplant 24:1125-1134|
|Christopher, Matthew J; Petti, Allegra A; Rettig, Michael P et al. (2018) Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. N Engl J Med 379:2330-2341|
|Trissal, Maria C; Wong, Terrence N; Yao, Juo-Chin et al. (2018) MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis. Cancer Res 78:3510-3521|
|Jacoby, Meagan A; Duncavage, Eric J; Chang, Gue Su et al. (2018) Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight 3:|
|Warner, Wayne A; Spencer, David H; Trissal, Maria et al. (2018) Expression profiling of snoRNAs in normal hematopoiesis and AML. Blood Adv 2:151-163|
|Bansal, Dhruv; Vij, Kiran; Chang, Gue Su et al. (2018) Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow. Haematologica 103:e270-e273|
|Xia, Jun; Miller, Christopher A; Baty, Jack et al. (2018) Somatic mutations and clonal hematopoiesis in congenital neutropenia. Blood 131:408-416|
|Fisher, D A C; Malkova, O; Engle, E K et al. (2017) Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia 31:1962-1974|
|Shirai, Cara Lunn; White, Brian S; Tripathi, Manorama et al. (2017) Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nat Commun 8:14060|
Showing the most recent 10 out of 122 publications